Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker Potential
Multiple sclerosis (MS) is a well-known, chronic autoimmune disorder of the central nervous system (CNS) involving demyelination and neurodegeneration. Research previously conducted in the area of the gut microbiome has highlighted it as a critical contributor to MS pathogenesis. Changes in the comm...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/14/4/435 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850155891976830976 |
|---|---|
| author | Mohammad Hosein Nemati Esmaeil Yazdanpanah Roya Kazemi Niloufar Orooji Sepehr Dadfar Valentyn Oksenych Dariush Haghmorad |
| author_facet | Mohammad Hosein Nemati Esmaeil Yazdanpanah Roya Kazemi Niloufar Orooji Sepehr Dadfar Valentyn Oksenych Dariush Haghmorad |
| author_sort | Mohammad Hosein Nemati |
| collection | DOAJ |
| description | Multiple sclerosis (MS) is a well-known, chronic autoimmune disorder of the central nervous system (CNS) involving demyelination and neurodegeneration. Research previously conducted in the area of the gut microbiome has highlighted it as a critical contributor to MS pathogenesis. Changes in the commensal microbiota, or dysbiosis, have been shown to affect immune homeostasis, leading to elevated levels of pro-inflammatory cytokines and disruption of the gut–brain axis. In this review, we provide a comprehensive overview of interactions between the gut microbiota and MS, especially focusing on the immunomodulatory actions of microbiota, such as influencing T-cell balance and control of metabolites, e.g., short-chain fatty acids. Various microbial taxa (e.g., <i>Prevotella</i> and <i>Faecalibacterium</i>) were suggested to lay protective roles, whereas <i>Akkermansia muciniphila</i> was associated with disease aggravation. Interventions focusing on microbiota, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary therapies to normalize gut microbial homeostasis, suppress inflammation and are proven to improve clinical benefits in MS patients. Alterations in gut microbiota represent opportunities for identifying biomarkers for early diagnosis, disease progression and treatment response monitoring. Further studies need to be conducted to potentially address the interplay between genetic predispositions, environmental cues, and microbiota composition to get the precise mechanisms of the gut–brain axis in MS. In conclusion, the gut microbiota plays a central role in MS pathogenesis and offers potential for novel therapeutic approaches, providing a promising avenue for improving clinical outcomes in MS management. |
| format | Article |
| id | doaj-art-5899c1ecf12d468286a10fbd96f50abd |
| institution | OA Journals |
| issn | 2079-7737 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology |
| spelling | doaj-art-5899c1ecf12d468286a10fbd96f50abd2025-08-20T02:24:44ZengMDPI AGBiology2079-77372025-04-0114443510.3390/biology14040435Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker PotentialMohammad Hosein Nemati0Esmaeil Yazdanpanah1Roya Kazemi2Niloufar Orooji3Sepehr Dadfar4Valentyn Oksenych5Dariush Haghmorad6Student Research Committee, Semnan University of Medical Sciences, Semnan 3514799442, IranImmunology Research Center, Mashhad University of Medical Sciences, Mashhad 9177948564, IranStudent Research Committee, Semnan University of Medical Sciences, Semnan 3514799442, IranStudent Research Committee, Semnan University of Medical Sciences, Semnan 3514799442, IranStudent Research Committee, Semnan University of Medical Sciences, Semnan 3514799442, IranBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5020 Bergen, NorwayDepartment of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan 3514799442, IranMultiple sclerosis (MS) is a well-known, chronic autoimmune disorder of the central nervous system (CNS) involving demyelination and neurodegeneration. Research previously conducted in the area of the gut microbiome has highlighted it as a critical contributor to MS pathogenesis. Changes in the commensal microbiota, or dysbiosis, have been shown to affect immune homeostasis, leading to elevated levels of pro-inflammatory cytokines and disruption of the gut–brain axis. In this review, we provide a comprehensive overview of interactions between the gut microbiota and MS, especially focusing on the immunomodulatory actions of microbiota, such as influencing T-cell balance and control of metabolites, e.g., short-chain fatty acids. Various microbial taxa (e.g., <i>Prevotella</i> and <i>Faecalibacterium</i>) were suggested to lay protective roles, whereas <i>Akkermansia muciniphila</i> was associated with disease aggravation. Interventions focusing on microbiota, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary therapies to normalize gut microbial homeostasis, suppress inflammation and are proven to improve clinical benefits in MS patients. Alterations in gut microbiota represent opportunities for identifying biomarkers for early diagnosis, disease progression and treatment response monitoring. Further studies need to be conducted to potentially address the interplay between genetic predispositions, environmental cues, and microbiota composition to get the precise mechanisms of the gut–brain axis in MS. In conclusion, the gut microbiota plays a central role in MS pathogenesis and offers potential for novel therapeutic approaches, providing a promising avenue for improving clinical outcomes in MS management.https://www.mdpi.com/2079-7737/14/4/435gut microbiotamultiple sclerosisimmune modulationdysbiosistherapeutic interventions |
| spellingShingle | Mohammad Hosein Nemati Esmaeil Yazdanpanah Roya Kazemi Niloufar Orooji Sepehr Dadfar Valentyn Oksenych Dariush Haghmorad Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker Potential Biology gut microbiota multiple sclerosis immune modulation dysbiosis therapeutic interventions |
| title | Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker Potential |
| title_full | Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker Potential |
| title_fullStr | Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker Potential |
| title_full_unstemmed | Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker Potential |
| title_short | Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker Potential |
| title_sort | microbiota driven mechanisms in multiple sclerosis pathogenesis therapeutic strategies and biomarker potential |
| topic | gut microbiota multiple sclerosis immune modulation dysbiosis therapeutic interventions |
| url | https://www.mdpi.com/2079-7737/14/4/435 |
| work_keys_str_mv | AT mohammadhoseinnemati microbiotadrivenmechanismsinmultiplesclerosispathogenesistherapeuticstrategiesandbiomarkerpotential AT esmaeilyazdanpanah microbiotadrivenmechanismsinmultiplesclerosispathogenesistherapeuticstrategiesandbiomarkerpotential AT royakazemi microbiotadrivenmechanismsinmultiplesclerosispathogenesistherapeuticstrategiesandbiomarkerpotential AT niloufarorooji microbiotadrivenmechanismsinmultiplesclerosispathogenesistherapeuticstrategiesandbiomarkerpotential AT sepehrdadfar microbiotadrivenmechanismsinmultiplesclerosispathogenesistherapeuticstrategiesandbiomarkerpotential AT valentynoksenych microbiotadrivenmechanismsinmultiplesclerosispathogenesistherapeuticstrategiesandbiomarkerpotential AT dariushhaghmorad microbiotadrivenmechanismsinmultiplesclerosispathogenesistherapeuticstrategiesandbiomarkerpotential |